Year: 2025
Type: article
Abstract: Tumor-infiltrating lymphocytes (TILs) form a pivotal part of the immune system’s defense against cancer, and their density, composition, and spatial distribution reflect both tumor biology and the degree of host immune activation. Across multiple carcinoma types—including breast, lung, colorectal, ovarian, and head and neck cancers—recent clinical studies and meta-analyses have shown that high levels of TILs, especially CD8⁺ cytotoxic T cells, are consistently linked with improved prognosis and enhanced responsiveness to chemotherapy and immune checkpoint inhibitors. Standardized assessment tools, such as the Immunoscore in colorectal carcinoma and stromal TIL evaluation guidelines in breast cancer, have improved reproducibility and clinical relevance. TILs not only act as prognostic and predictive biomarkers but are also being harnessed as therapeutic agents in emerging immunotherapy strategies, including adoptive cell therapy. Despite these advances, variability in evaluation methods and the functional heterogeneity of TIL subsets remain challenges. Standardization of assessment protocols and deeper characterization of TIL phenotypes will be essential to fully integrate these immune markers into routine oncology practice and optimize their potential in precision medicine.
Source: Iranian journal of pathology
Authors: Gunvanti Rathod, Pragnesh Parmar
Institution: All India Institute of Medical Sciences Bibinagar
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $182
OpenAlex ID: W4417445215
FWCI:
Cites:
Cited by:
Related to: